Shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) were up 5.7% during trading on Monday . The company traded as high as $2.05 and last traded at $2.04. Approximately 816,000 shares were traded during trading, an increase of 12% from the average daily volume of 728,859 shares. The stock had previously closed at $1.93.
A number of analysts recently commented on BLPH shares. Zacks Investment Research raised shares of Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a report on Friday, September 15th. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Bellerophon Therapeutics in a research report on Wednesday, September 6th. Finally, ValuEngine upgraded shares of Bellerophon Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 8th.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. VHCP Management II LLC acquired a new position in Bellerophon Therapeutics during the third quarter worth about $4,720,000. Susquehanna International Group LLP acquired a new position in shares of Bellerophon Therapeutics in the second quarter valued at approximately $1,316,000. Vanguard Group Inc. raised its position in shares of Bellerophon Therapeutics by 52.6% in the second quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock valued at $821,000 after buying an additional 211,111 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of Bellerophon Therapeutics in the first quarter valued at approximately $125,000. Finally, Renaissance Technologies LLC raised its position in shares of Bellerophon Therapeutics by 99.7% in the first quarter. Renaissance Technologies LLC now owns 477,400 shares of the biotechnology company’s stock valued at $711,000 after buying an additional 238,300 shares during the last quarter. Institutional investors own 43.55% of the company’s stock.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.
What are top analysts saying about Bellerophon Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bellerophon Therapeutics Inc. and related companies.